-
Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
Tuesday, May 14, 2024 - 8:00am | 623Read More...Psychedelics biotech firm, Enveric Biosciences (NASDAQ:ENVB) has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, British Columbia-based biopharma company MindBio Therapeutics Corp CSE: MBIO, which is pioneering novel treatments for psychiatric...
-
MindBio Begins Recruitment Of Participants For LSD-Microdosing Clinical Trial In Cancer Patients Experiencing Emotional Distress
Tuesday, July 25, 2023 - 9:12am | 462Read More...MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6) has started selection of participants for its phase 2 randomized double-blind and placebo controlled clinical trial in advanced stage cancer patients using microdoses of lysergic acid diethylamide (LSD) and meaning centered psychotherapy in an...
-
MindBio Phase 2 LSD-Microdosing Clinical Trial In Patients With Major Depressive Disorder Begins Pre-Screening Participants
Wednesday, July 19, 2023 - 10:06am | 341Read More...MindBio Therapeutics Corp. (CSE:MBIO) (Frankfurt:WF6) have started pre-screening for participant entry into phase 2 LSD-microdosing clinical trials. The clinical trials are a for take home use of MindBio's LSD-microdosing treatment. The initial phase 2a open label trial will assess the...
